Brainstorm Cell Therapeutics, Inc.
BCLI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.49M
Close$
$-0.02
102.3% downside
Current Fair Value
102.3% downsideOvervalued by 102.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $9.49 Million |
|---|---|
| Enterprise Value | $10.84 Million |
| Earnings per Share | $-1.11 |
| Beta | 0.24 |
| Outstanding Shares | 11,034,775 |
Return
| Return on Equity | -120.42% |
|---|---|
| Return on Assets | 3039.41% |
| Return on Invested Capital | -47.53% |
Valuation & Multiples
| P/E Ratio | -0.91 |
|---|---|
| PEG | -2.76 |
| Price to Sales | - |
| Price to Book Ratio | -0.41 |
| Enterprise Value to Revenue | 12.31 |
| Enterprise Value to EBIT | 1.91 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | -0.12 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.29
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.18
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 3.69% |
|---|---|
| Total Invested | $1,727▼ 99.35% |
| Investors Holding | 5▼ 28.00% |
About Brainstorm Cell Therapeutics, Inc.
CEO: Chaim Lebovits
